Genome-Wide/NN
Association/NN
Study/NN
of/IN
Medication/NN
Adherence/NN
in/IN
Chronic/JJ
Diseases/NNS
in/IN
the/DT
Korean/JJ
Population/NN
./.
====================
Medication/NN
adherence/NN
is/VBZ
generally/RB
defined/VBN
as/IN
the/DT
extent/NN
of/IN
voluntary/NN
cooperation/NN
of/IN
a/DT
patient/NN
in/IN
taking/VBG
medicine/NN
as/IN
prescribed/VBN
./.
====================
Adherence/NN
to/TO
long-term/JJ
treatment/NN
with/IN
chronic/JJ
disease/NN
is/VBZ
essential/JJ
for/IN
reducing/VBG
disease/NN
comorbidity/NN
and/CC
mortality/NN
./.
====================
However/RB
,/,
medication/NN
non-adherence/NN
in/IN
chronic/JJ
disease/NN
averages/VBZ
50/CD
%/NN
./.
====================
This/DT
study/NN
was/VBD
conducted/VBN
a/DT
genome-wide/NN
association/NN
study/NN
to/TO
identify/VB
the/DT
genetic/JJ
basis/NN
of/IN
medication/NN
adherence/NN
./.
====================
A/DT
total/JJ
of/IN
235/CD
medication/NN
non-adherents/NNS
and/CC
1,067/CD
medication/NN
adherents/NNS
with/IN
hypertension/NN
or/CC
diabetes/NNS
were/VBD
used/VBN
from/IN
the/DT
Korean/JJ
Association/NN
Resource/NN
project/VB
data/NNS
according/VBG
to/TO
the/DT
self-reported/JJ
treatment/NN
status/NN
of/IN
each/DT
chronic/JJ
disease/NN
,/,
respectively/RB
./.
====================
We/PRP
identified/VBD
four/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
with/IN
suggestive/JJ
genome-wide/NN
association/NN
./.
====================
The/DT
most/JJS
significant/JJ
single/JJ
nucleotide/NN
polymorphism/NN
was/VBD
rs6978712/NN
(/(
chromosome/NN
7/CD
,/,
p/NN
=/JJ
4.87/CD
×/CD
10-7/CD
)/)
,/,
which/WDT
is/VBZ
located/JJ
proximal/JJ
to/TO
the/DT
GCC1/NN
gene/NN
,/,
which/WDT
was/VBD
previously/RB
implicated/VBN
in/IN
decision-making/VBG
capability/NN
in/IN
drug/NN
abusers/NNS
./.
====================
Two/CD
suggestive/JJ
single/JJ
nucleotide/NN
polymorphisms/NNS
were/VBD
in/IN
strong/JJ
linkage/NN
disequilibrium/NN
(/(
r2/NN
>/JJR
0.8/CD
)/)
with/IN
rs6978712/NN
./.
====================
Thus/RB
,/,
in/IN
the/DT
aspect/NN
of/IN
decision-making/VBG
in/IN
adherence/NN
behavior/NN
,/,
the/DT
association/NN
between/IN
medication/NN
adherence/NN
and/CC
three/CD
loci/NNS
proximal/JJ
to/TO
the/DT
GCC1/NN
gene/NN
seems/VBZ
worthy/NN
of/IN
further/JJ
research/NN
./.
====================
However/RB
,/,
to/TO
overcome/VB
a/DT
few/JJ
limitations/NNS
in/IN
this/DT
study/NN
,/,
defining/VBG
the/DT
standardized/VBN
phenotype/NN
criteria/NNS
for/IN
self-reported/JJ
adherence/NN
should/MD
be/VB
performed/VBN
before/IN
replicating/VBG
association/NN
studies/NNS
./.
====================
Medication/NN
adherence/NN
is/VBZ
generally/RB
defined/VBN
as/IN
the/DT
extent/NN
to/TO
which/WDT
patient/NN
take/VBP
medications/NNS
to/TO
coincide/VB
with/IN
the/DT
healthcare/JJ
provider/NN
's/POS
recommendation/NN
[/(
1/CD
]/)
./.
====================
Adherence/NN
to/TO
long-term/JJ
treatment/NN
in/IN
chronic/JJ
disease/NN
,/,
such/JJ
as/IN
hypertension/NN
and/CC
diabetes/VBZ
,/,
is/VBZ
essential/JJ
for/IN
reducing/VBG
the/DT
risks/NNS
of/IN
disease/NN
comorbidity/NN
and/CC
mortality/NN
[/(
2/CD
]/)
./.
====================
Poor/JJ
adherence/NN
to/TO
medication/NN
can/MD
cause/VB
worsening/VBG
of/IN
disease/NN
,/,
death/NN
,/,
and/CC
increased/VBD
financial/JJ
burden/NN
for/IN
society/NN
[/(
1/CD
]/)
./.
====================
Most/JJS
cases/NNS
of/IN
hypertension/NN
and/CC
diabetes/VBZ
are/VBP
inextirpable/JJ
./.
====================
The/DT
main/JJ
goal/NN
of/IN
treatment/NN
for/IN
these/DT
chronic/JJ
diseases/NNS
is/VBZ
to/TO
delay/VB
disease/NN
progression/NN
and/CC
to/TO
prevent/VB
developing/VBG
complications/NNS
./.
====================
Thus/RB
,/,
medication/NN
adherence/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
important/JJ
factors/NNS
for/IN
success/NN
in/IN
lifelong/JJ
treatment/NN
[/(
3/CD
]/)
./.
====================
However/RB
,/,
medication/NN
non-adherence/NN
in/IN
chronic/JJ
disease/NN
averages/VBZ
50/CD
%/NN
[/(
4/CD
]/)
./.
====================
The/DT
World/NN
Health/NN
Organization/NN
reported/VBD
that/IN
non-adherence/NN
is/VBZ
a/DT
leading/VBG
cause/VBP
of/IN
preventable/JJ
death/NN
and/CC
cost/JJ
./.
====================
Predictors/NNS
of/IN
poor/JJ
adherence/NN
are/VBP
a/DT
useful/JJ
indicator/NN
for/IN
physicians/NNS
to/TO
identify/VB
patients/NNS
who/WP
are/VBP
most/RBS
in/IN
need/NN
of/IN
interventions/NNS
to/TO
improve/VB
adherence/NN
[/(
1/CD
]/)
./.
====================
Illness/RB
perceptions/NNS
and/CC
self-efficacy/NN
are/VBP
powerful/JJ
predictors/NNS
of/IN
adherence/NN
[/(
2/CD
]/)
./.
====================
These/DT
health-related/JJ
cognitions/NNS
have/VBP
associations/NNS
with/IN
personality/NN
,/,
and/CC
personality/NN
traits/VBZ
can/MD
be/VB
conveniently/RB
summarized/VBD
by/IN
a/DT
five-factor/NN
model/NN
of/IN
personality/NN
(/(
conscientiousness/RB
,/,
neuroticism/NN
,/,
agreeableness/RB
,/,
extraversion/NN
,/,
and/CC
openness/RB
)/)
[/(
5/CD
]/)
./.
====================
Several/JJ
studies/NNS
have/VBP
explored/VBN
the/DT
associations/NNS
between/IN
personality/NN
and/CC
adherence/NN
./.
====================
Among/IN
the/DT
12/CD
previous/JJ
publications/NNS
exploring/VBG
associations/NNS
between/IN
personality/NN
traits/VBZ
and/CC
medication/NN
adherence/NN
,/,
7/CD
studies/NNS
reported/VBD
that/IN
medication/NN
adherence/NN
has/VBZ
been/VBN
positively/RB
related/JJ
to/TO
conscientiousness/VB
,/,
5/CD
studies/NNS
reported/VBD
negative/JJ
relationships/NNS
with/IN
neuroticism/NN
,/,
2/CD
studies/NNS
reported/VBD
about/IN
agreeableness/RB
with/IN
positive/JJ
associations/NNS
,/,
and/CC
1/CD
study/NN
reported/VBD
a/DT
positive/JJ
relationship/NN
with/IN
extraversion/NN
[/(
6/CD
,/,
7/CD
,/,
8/CD
]/)
./.
====================
A/DT
genetic/JJ
basis/NN
of/IN
personality/NN
traits/VBZ
has/VBZ
been/VBN
identified/VBN
from/IN
behavior/NN
genetic/JJ
studies/NNS
./.
====================
Twin/NN
,/,
adoption/NN
,/,
and/CC
family/NN
studies/NNS
show/VBP
that/IN
heritability/NN
of/IN
personality/NN
is/VBZ
about/RB
50/CD
%/NN
[/(
9/CD
]/)
./.
====================
Several/JJ
studies/NNS
have/VBP
attempted/VBN
to/TO
identify/VB
candidate/NN
genes/NNS
with/IN
five/CD
dimensions/NNS
of/IN
personality/NN
,/,
but/CC
the/DT
results/NNS
were/VBD
inconclusive/JJ
./.
====================
Genetic/JJ
linkage/NN
studies/NNS
have/VBP
suggested/VBN
only/RB
a/DT
few/JJ
genomic/JJ
regions/NNS
for/IN
personality/NN
traits/VBZ
./.
====================
The/DT
genetic/JJ
influences/VBZ
on/IN
personality/NN
traits/VBZ
are/VBP
likely/JJ
attributable/JJ
to/TO
many/JJ
genes/NNS
with/IN
small/JJ
effects/NNS
./.
====================
Few/JJ
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
have/VBP
identified/VBN
genetic/JJ
variants/NNS
associated/VBN
with/IN
personality/NN
traits/VBZ
./.
====================
However/RB
,/,
most/JJS
of/IN
the/DT
associations/NNS
with/IN
personality/NN
traits/VBZ
could/MD
not/RB
be/VB
replicated/VBN
,/,
except/IN
in/IN
one/CD
study/NN
[/(
8/CD
]/)
./.
====================
Unlike/IN
the/DT
attempts/NNS
to/TO
elucidate/VB
the/DT
genomic/JJ
associations/NNS
of/IN
personality/NN
,/,
there/EX
is/VBZ
no/DT
research/NN
on/IN
the/DT
genetic/JJ
aspect/NN
of/IN
medication/NN
adherence/NN
until/IN
now/RB
./.
====================
We/PRP
assumed/VBD
that/IN
medication/NN
adherence/NN
has/VBZ
a/DT
genetic/JJ
background/NN
,/,
as/IN
the/DT
personality/NN
traits/VBZ
that/DT
affect/VBP
medication/NN
adherence/NN
have/VBP
a/DT
genetic/JJ
basis/NN
for/IN
heritability/NN
./.
====================
Therefore/RB
,/,
we/PRP
conducted/VBD
a/DT
GWAS/JJ
to/TO
identify/VB
the/DT
association/NN
between/IN
medication/NN
adherence/NN
and/CC
genotype/NN
./.
====================
Study/NN
subjects/NNS
====================
A/DT
nested/JJ
case-control/JJ
study/NN
of/IN
medication/NN
adherence/NN
in/IN
chronic/JJ
diseases/NNS
(/(
hypertension/NN
or/CC
diabetes/NNS
)/)
was/VBD
conducted/VBN
within/IN
the/DT
Korean/JJ
Association/NN
Resource/NN
(/(
KARE/NN
)/)
project/VBP
data/NNS
(/(
which/WDT
included/VBD
genotypes/NNS
from/IN
8,842/CD
participants/NNS
from/IN
the/DT
rural/JJ
Anseong/JJ
and/CC
urban/JJ
Ansan/NN
cohorts/NNS
as/IN
part/NN
of/IN
the/DT
Korean/JJ
Genome/NN
Epidemiology/JJ
Study/NN
)/)
[/(
10/CD
]/)
./.
====================
Two/CD
groups/NNS
were/VBD
extracted/VBN
from/IN
the/DT
KARE/NN
data/NNS
,/,
one/CD
of/IN
medication/NN
non-adherents/NNS
with/IN
chronic/JJ
disease/NN
(/(
cases/NNS
)/)
and/CC
the/DT
other/JJ
of/IN
medication/NN
adherents/NNS
with/IN
chronic/JJ
disease/NN
(/(
controls/NNS
)/)
,/,
based/VBN
on/IN
the/DT
following/VBG
procedure/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
There/EX
were/VBD
1,387/CD
and/CC
613/CD
individuals/NNS
who/WP
were/VBD
diagnosed/VBN
with/IN
hypertension/NN
and/CC
diabetes/VBZ
,/,
respectively/RB
,/,
of/IN
a/DT
total/JJ
of/IN
8,842/CD
;/:
1,540/CD
individuals/NNS
were/VBD
defined/VBN
as/IN
patients/NNS
with/IN
chronic/JJ
disease/NN
after/IN
excluding/VBG
230/CD
patients/NNS
with/IN
comorbid/JJ
hypertension/NN
and/CC
diabetes/VBZ
./.
====================
Among/IN
1,540/CD
patients/NNS
with/IN
chronic/JJ
disease/NN
,/,
a/DT
patient/NN
who/WP
was/VBD
undergoing/VBG
treatment/NN
for/IN
hypertension/NN
or/CC
diabetes/NNS
or/CC
who/WP
was/VBD
taking/VBG
hypertensive/JJ
or/CC
diabetes/NNS
medicines/NNS
(/(
including/VBG
insulin/NN
)/)
were/VBD
classified/VBN
as/IN
the/DT
control/NN
group/NN
(/(
n/NN
=/JJ
1,072/CD
)/)
./.
====================
Patients/NNS
who/WP
was/VBD
not/RB
receiving/VBG
treatment/NN
or/CC
taking/VBG
medicines/NNS
were/VBD
classified/VBN
as/IN
the/DT
case/NN
group/NN
(/(
n/NN
=/JJ
239/CD
)/)
./.
====================
Individuals/NNS
whose/WP$
information/NN
about/IN
treatment/NN
was/VBD
not/RB
provided/VBN
were/VBD
removed/VBN
(/(
n/NN
=/JJ
229/CD
)/)
./.
====================
Consequently/RB
,/,
235/CD
cases/NNS
and/CC
1,067/CD
controls/NNS
were/VBD
used/VBN
for/IN
the/DT
GWAS/NN
after/IN
excluding/VBG
9/CD
patients/NNS
with/IN
comorbid/JJ
psychotic/JJ
disorders/NNS
or/CC
cognitive/JJ
disorders/NNS
,/,
such/JJ
as/IN
dementia/VBN
[/(
1/CD
]/)
./.
====================
Genotyping/VBG
====================
The/DT
genotyping/JJ
and/CC
quality/NN
control/NN
procedures/NNS
for/IN
the/DT
KARE/NN
data/NNS
have/VBP
been/VBN
described/VBN
previously/RB
[/(
10/CD
]/)
./.
====================
Single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
with/IN
a/DT
high/JJ
missing/VBG
gene/NN
call/JJ
rate/NN
(/(
>/JJR
5/CD
%/NN
)/)
,/,
low/JJ
minor/JJ
allele/NN
frequency/NN
(/(
</JJR
0.05/CD
)/)
,/,
and/CC
significant/JJ
deviation/NN
from/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
p/NN
≤/CD
0.001/CD
)/)
were/VBD
excluded/VBN
,/,
leaving/VBG
a/DT
total/JJ
of/IN
311,493/CD
SNPs/NNS
to/TO
be/VB
examined/VBN
./.
====================
Statistical/JJ
analyses/NNS
====================
The/DT
case-control/JJ
GWAS/NN
was/VBD
conducted/VBN
using/VBG
PLINK/NN
software/JJ
version/NN
1.07/CD
[/(
11/CD
]/)
./.
====================
A/DT
quantile-quantile/JJ
(/(
QQ/NN
)/)
plot/NN
and/CC
a/DT
Manhattan/JJ
plot/NN
were/VBD
produced/VBN
using/VBG
the/DT
R/NN
statistics/NNS
package/NN
[/(
12/CD
]/)
./.
====================
A/DT
regional/JJ
plot/NN
was/VBD
generated/VBN
using/VBG
LocusZoom/JJ
1.1/CD
[/(
13/CD
]/)
./.
====================
Student/JJ
's/POS
t-test/JJS
and/CC
Fisher/RB
's/POS
exact/JJ
test/NN
were/VBD
used/VBN
to/TO
test/VB
differences/NNS
in/IN
basic/JJ
and/CC
clinical/JJ
characteristics/NNS
between/IN
case/NN
and/CC
control/NN
groups/NNS
./.
====================
Characteristics/NNS
of/IN
study/NN
subjects/NNS
====================
The/DT
general/JJ
and/CC
clinical/JJ
characteristics/NNS
of/IN
the/DT
case/NN
and/CC
control/NN
groups/NNS
are/VBP
described/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
case/NN
group/NN
(/(
non-adherents/NNS
)/)
consisted/VBD
of/IN
80/CD
subjects/NNS
with/IN
diabetes/NNS
and/CC
155/CD
individuals/NNS
with/IN
hypertension/NN
,/,
and/CC
the/DT
control/NN
group/NN
(/(
adherents/NNS
)/)
consisted/VBD
of/IN
240/CD
and/CC
827/CD
,/,
respectively/RB
./.
====================
Individuals/NNS
with/IN
diabetes/NNS
tended/VBD
to/TO
adhere/VB
less/RBR
to/TO
medication/NN
than/IN
hypertensive/JJ
patients/NNS
[/(
14/CD
]/)
./.
====================
The/DT
mean/JJ
age/NN
of/IN
the/DT
case/NN
group/NN
was/VBD
54.29/CD
±/CD
8.10/CD
and/CC
57.66/CD
±/CD
7.90/CD
years/NNS
in/IN
the/DT
control/NN
group/NN
./.
====================
Adherents/NNS
were/VBD
significantly/RB
older/JJR
than/IN
non-adherents/NNS
./.
====================
Males/NNS
were/VBD
less/RBR
adherent/JJ
than/IN
females/NNS
./.
====================
All/DT
results/NNS
above/VBP
are/VBP
consistent/JJ
with/IN
previous/JJ
studies/NNS
of/IN
factors/NNS
affecting/VBG
medication/NN
adherence/NN
[/(
3/CD
]/)
./.
====================
Among/IN
the/DT
clinical/JJ
characteristics/NNS
,/,
diastolic/JJ
blood/NN
pressure/NN
in/IN
hypertensive/JJ
individuals/NNS
was/VBD
higher/JJR
in/IN
the/DT
non-adherence/NN
group/NN
./.
====================
However/RB
,/,
systolic/JJ
blood/NN
pressure/NN
in/IN
hypertensive/JJ
patients/NNS
and/CC
fasting/JJ
plasma/NN
glucose/NN
in/IN
diabetic/JJ
person/NN
were/VBD
similar/JJ
between/IN
adherence/NN
and/CC
non-adherence/NN
groups/NNS
./.
====================
The/DT
rates/NNS
of/IN
family/NN
history/NN
of/IN
hypertension/NN
,/,
diabetes/VBZ
,/,
and/CC
their/PRP$
life-threatening/JJ
complications/NNS
,/,
such/JJ
as/IN
cerebrovascular/JJ
attack/NN
and/CC
coronary/JJ
artery/NN
disease/NN
,/,
did/VBD
not/RB
differ/VB
between/IN
case/NN
and/CC
control/NN
groups/NNS
./.
====================
SNPs/NNS
associated/VBN
with/IN
medication/NN
adherence/NN
====================
The/DT
GWAS/NN
for/IN
medication/NN
adherence/NN
in/IN
1,067/CD
medication/NN
adherents/NNS
and/CC
235/CD
medication/NN
non-adherents/NNS
showed/VBD
multiple/JJ
SNPs/NNS
with/IN
a/DT
suggestive/JJ
association/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
QQ/NN
plot/NN
showed/VBD
that/IN
most/JJS
of/IN
the/DT
observed/VBN
associations/NNS
lay/NN
close/JJ
to/TO
the/DT
expected/VBN
distribution/NN
,/,
conforming/VBG
to/TO
the/DT
null/JJ
hypothesis/NN
of/IN
no/DT
association/NN
./.
====================
The/DT
genomic/JJ
inflation/NN
factor/NN
was/VBD
1.00/CD
,/,
indicating/VBG
no/DT
evidence/NN
of/IN
inflation/NN
in/IN
the/DT
test/NN
statistics/NNS
due/JJ
to/TO
population/NN
stratification/NN
or/CC
other/JJ
sources/NNS
./.
====================
SNPs/NNS
with/IN
a/DT
suggestive/JJ
genome-wide/NN
association/NN
(/(
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
are/VBP
shown/VBN
in/IN
Table/JJ
2/CD
./.
====================
Although/IN
no/DT
SNP/NN
met/NN
the/DT
criteria/NNS
of/IN
genome-wide/NN
significance/NN
(/(
p/NN
</JJR
5/CD
×/NN
10-8/CD
)/)
,/,
four/CD
loci/NNS
(/(
rs6978712/NN
,/,
rs10487488/NN
,/,
rs7690819/NN
,/,
rs11973012/NN
)/)
with/IN
suggestive/JJ
significance/NN
were/VBD
identified/VBN
./.
====================
The/DT
most/JJS
significant/JJ
SNP/NN
was/VBD
rs6978712/NN
(/(
p/NN
=/JJ
4.87/CD
×/CD
10-7/CD
)/)
,/,
which/WDT
is/VBZ
located/JJ
proximal/JJ
to/TO
the/DT
GCC1/NN
gene/NN
,/,
which/WDT
was/VBD
previously/RB
implicated/VBN
in/IN
decision-making/VBG
capability/NN
in/IN
drug/NN
abusers/NNS
[/(
15/CD
]/)
./.
====================
Three/CD
SNPs/NNS
on/IN
chromosome/NN
7/CD
were/VBD
in/IN
close/JJ
proximity/NN
,/,
and/CC
Fig/NN
./.
====================
3/CD
shows/VBZ
a/DT
regional/JJ
association/NN
for/IN
these/DT
SNPs/NNS
proximal/JJ
to/TO
the/DT
GCC1/NN
gene/NN
./.
====================
Medication/NN
adherence/NN
averages/VBZ
only/RB
50/CD
%/NN
among/IN
patients/NNS
receiving/VBG
treatment/NN
for/IN
chronic/JJ
diseases/NNS
./.
====================
Poor/JJ
medication/NN
adherence/NN
contributes/VBZ
to/TO
worsening/VBG
disease/NN
,/,
death/NN
,/,
and/CC
increased/VBD
health/NN
care/NN
costs/NNS
./.
====================
Moreover/RB
,/,
if/IN
medication/NN
adherence/NN
is/VBZ
not/RB
guaranteed/JJ
,/,
new/JJ
therapeutic/JJ
options/NNS
,/,
such/JJ
as/IN
personalized/VBN
medicine/NN
that/DT
aims/VBZ
to/TO
customize/VB
healthcare/JJ
to/TO
individual/JJ
patients/NNS
based/VBN
on/IN
their/PRP$
genetic/JJ
background/NN
,/,
are/VBP
merely/RB
useless/RB
[/(
16/CD
]/)
./.
====================
However/RB
,/,
in/IN
spite/NN
of/IN
its/PRP$
importance/NN
in/IN
personal/JJ
and/CC
social/JJ
aspects/NNS
,/,
the/DT
genetic/JJ
background/NN
for/IN
medication/NN
adherence/NN
has/VBZ
never/RB
been/VBN
studied/VBN
./.
====================
Since/IN
personality/NN
traits/VBZ
that/DT
have/VBP
a/DT
genetic/JJ
background/NN
affect/VB
behaviors/NNS
,/,
including/VBG
medication/NN
non-adherence/NN
,/,
this/DT
study/NN
aimed/VBD
to/TO
explore/VB
the/DT
genetic/JJ
basis/NN
of/IN
medication/NN
adherence/NN
in/IN
chronic/JJ
diseases/NNS
for/IN
the/DT
first/JJ
time/NN
./.
====================
Among/IN
the/DT
hypertensive/JJ
or/CC
diabetic/JJ
patients/NNS
from/IN
the/DT
KARE/NN
cohort/NN
study/NN
,/,
235/CD
medication/NN
non-adherent/JJ
individuals/NNS
(/(
case/NN
)/)
and/CC
1,067/CD
medication/NN
adherent/JJ
individuals/NNS
(/(
control/NN
)/)
were/VBD
extracted/VBN
according/VBG
to/TO
the/DT
self-reported/JJ
treatment/NN
status/NN
for/IN
the/DT
disease/NN
from/IN
the/DT
cohort/JJ
questionnaire/RB
./.
====================
Patient/JJ
self-reports/NNS
are/VBP
considered/VBN
a/DT
simple/JJ
and/CC
effective/JJ
method/NN
to/TO
measure/VB
adherence/NN
,/,
since/IN
a/DT
gold/NN
standard/JJ
does/VBZ
not/RB
exist/VB
[/(
1/CD
]/)
./.
====================
Patients/NNS
with/IN
cognitive/JJ
impairments/NNS
that/IN
can/MD
affect/VB
adherence/NN
were/VBD
excluded/VBN
./.
====================
Defining/VBG
rigorous/JJ
phenotype/NN
criteria/NNS
is/VBZ
paramount/JJ
to/TO
the/DT
success/NN
of/IN
a/DT
case-control/JJ
GWAS/NN
[/(
17/CD
]/)
./.
====================
Thus/RB
,/,
the/DT
method/NN
of/IN
classifying/VBG
individuals/NNS
as/IN
either/CC
case/NN
or/CC
control/JJ
in/IN
this/DT
study/NN
was/VBD
validated/VBN
by/IN
comparing/VBG
the/DT
general/JJ
characteristics/NNS
of/IN
the/DT
case-control/JJ
subjects/NNS
./.
====================
The/DT
differences/NNS
in/IN
demographic/JJ
factors/NNS
(/(
age/NN
and/CC
gender/NN
)/)
and/CC
disease/NN
factors/NNS
for/IN
adherence/NN
between/IN
the/DT
two/CD
groups/NNS
were/VBD
consistent/JJ
with/IN
previous/JJ
reports/NNS
(/(
Table/JJ
1/CD
)/)
[/(
3/CD
]/)
./.
====================
Nevertheless/RB
,/,
the/DT
classification/NN
criteria/NNS
in/IN
this/DT
study/NN
have/VBP
limitations/NNS
./.
====================
First/RB
,/,
there/EX
is/VBZ
the/DT
possibility/NN
of/IN
misclassification/NN
of/IN
treatment-adherent/JJ
individuals/NNS
as/IN
medication/NN
non-adherent/JJ
patients/NNS
,/,
because/IN
the/DT
criteria/NNS
were/VBD
based/VBN
exclusively/RB
on/IN
current/JJ
medication/NN
status/NN
for/IN
hypertension/NN
or/CC
diabetes/NNS
./.
====================
For/IN
example/NN
,/,
patients/NNS
with/IN
mild/JJ
hypertension/NN
or/CC
diabetes/NNS
who/WP
follow/VBP
instructions/NNS
from/IN
the/DT
physician/JJ
to/TO
modify/VB
their/PRP$
diet/NN
or/CC
lifestyle/JJ
as/IN
an/DT
initial/JJ
therapy/NN
can/MD
be/VB
classified/VBN
as/IN
medication/NN
non-adherent/JJ
individuals/NNS
./.
====================
Second/RB
,/,
the/DT
different/JJ
ratio/NN
of/IN
the/DT
number/NN
of/IN
hypertensive/JJ
and/CC
diabetic/JJ
patients/NNS
between/IN
the/DT
case/NN
and/CC
control/NN
groups/NNS
can/MD
affect/VB
the/DT
GWAS/NN
results/NNS
[/(
18/CD
]/)
./.
====================
Additionally/RB
,/,
the/DT
risk/NN
of/IN
volunteer/NN
bias/NNS
is/VBZ
present/JJ
,/,
in/IN
which/WDT
individuals/NNS
who/WP
participated/JJ
in/IN
the/DT
KARE/NN
cohort/NN
possibly/RB
tended/VBN
to/TO
adhere/VB
more/RBR
to/TO
health/NN
care/JJ
services/VBZ
./.
====================
To/TO
overcome/VB
these/DT
limitations/NNS
,/,
standardized/VBD
phenotype/NN
criteria/NNS
for/IN
self-reported/JJ
adherence/NN
,/,
such/JJ
as/IN
the/DT
five-item/NN
Medication/NN
Adherence/NN
Report/NN
Scale-MARS-5/NN
,/,
which/WDT
has/VBZ
already/RB
been/VBN
used/VBN
in/IN
various/JJ
settings/NNS
[/(
19/CD
]/)
,/,
and/CC
the/DT
eight-item/NN
Morisky/NNP
Medication/NN
Adherence/NN
Scale-MMAS-8/NN
,/,
which/WDT
has/VBZ
been/VBN
validated/VBN
in/IN
over/IN
1,000/CD
individuals/NNS
with/IN
hypertension/NN
[/(
20/CD
]/)
,/,
can/MD
be/VB
applied/VBN
in/IN
the/DT
study/NN
design/IN
./.
====================
These/DT
criteria/NNS
enable/VBP
reliable/JJ
and/CC
replicable/JJ
classification/NN
of/IN
medication/NN
adherence/NN
[/(
17/CD
]/)
./.
====================
This/DT
study/NN
identified/VBD
four/CD
loci/NNS
that/IN
were/VBD
suggestively/RB
associated/VBN
with/IN
medication/NN
adherence/NN
./.
====================
The/DT
most/JJS
significantly/RB
associated/VBN
SNP/NN
was/VBD
rs6978712/NN
(/(
p/NN
=/JJ
4.87/CD
×/CD
10-7/CD
)/)
,/,
which/WDT
is/VBZ
located/JJ
nearby/RB
the/DT
GCC1/NN
gene/NN
on/IN
chromosome/NN
7/CD
./.
====================
Two/CD
suggestive/JJ
SNPs/NNS
were/VBD
in/IN
strong/JJ
linkage/NN
disequilibrium/NN
(/(
r2/NN
>/JJR
0.8/CD
)/)
with/IN
rs6978712/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
This/DT
might/MD
be/VB
due/JJ
to/TO
the/DT
close/JJ
physical/JJ
proximity/NN
of/IN
those/DT
three/CD
SNPs/NNS
./.
====================
GCC1/NN
encodes/VBZ
a/DT
peripheral/JJ
membrane/NN
protein/NN
that/WDT
may/MD
have/VB
a/DT
role/NN
in/IN
the/DT
organization/NN
of/IN
the/DT
trans-Golgi/JJ
network/NN
subcompartment/JJ
that/DT
is/VBZ
associated/VBN
with/IN
membrane/NN
transport/NN
[/(
21/CD
]/)
./.
====================
The/DT
trans-Golgi/JJ
network/NN
is/VBZ
a/DT
major/JJ
secretory/JJ
pathway/NN
that/WDT
sorts/VBZ
and/CC
directs/VBZ
newly/RB
synthesized/VBN
proteins/NNS
to/TO
subcellular/JJ
destinations/NNS
,/,
including/VBG
neuronal/JJ
synapses/NNS
./.
====================
Increased/VBN
transcription/NN
of/IN
GCC1/NN
in/IN
the/DT
brain/NN
cortex/NN
of/IN
drug/NN
abusers/NNS
has/VBZ
been/VBN
reported/VBN
in/IN
one/CD
study/NN
[/(
15/CD
]/)
./.
====================
This/DT
study/NN
indicates/VBZ
that/IN
GCC1/NN
is/VBZ
involved/VBN
in/IN
decision-making/VBG
capabilities/NNS
in/IN
drug/NN
abusers/NNS
./.
====================
Patients/NNS
with/IN
chronic/JJ
diseases/NNS
weigh/JJ
the/DT
benefits/NNS
from/IN
adherence/NN
with/IN
treatment/NN
against/IN
the/DT
constraints/NNS
on/IN
their/PRP$
daily/RB
lives/NNS
and/CC
the/DT
perceived/JJ
risks/NNS
of/IN
treatment/NN
,/,
such/JJ
as/IN
side/JJ
effects/NNS
,/,
time/NN
,/,
money/NNP
,/,
and/CC
effort/NN
involved/VBN
,/,
either/CC
consciously/RB
or/CC
subconsciously/RB
[/(
3/CD
]/)
./.
====================
Thus/RB
,/,
in/IN
the/DT
aspect/NN
of/IN
decision-making/VBG
in/IN
adherence/NN
behavior/NN
,/,
the/DT
association/NN
between/IN
medication/NN
adherence/NN
and/CC
the/DT
three/CD
SNPs/NNS
proximal/JJ
to/TO
the/DT
GCC1/NN
gene/NN
identified/VBD
in/IN
this/DT
study/NN
seems/VBZ
worthy/NN
of/IN
further/JJ
research/NN
./.
====================
The/DT
personality/NN
trait-associated/VBN
SNPs/NNS
were/VBD
not/RB
associated/VBN
with/IN
medication/NN
adherence/NN
in/IN
this/DT
study/NN
./.
====================
Because/IN
of/IN
the/DT
multivariate/JJ
association/NN
between/IN
personality/NN
traits/VBZ
and/CC
medication/NN
adherence/NN
,/,
it/PRP
seems/VBZ
difficult/JJ
to/TO
apply/RB
the/DT
personality/NN
trait-associated/VBN
SNPs/NNS
to/TO
the/DT
medication/NN
adherence-associated/JJ
SNPs/NNS
directly/RB
./.
====================
This/DT
study/NN
suggests/VBZ
potential/JJ
evidence/NN
for/IN
a/DT
genetic/JJ
basis/NN
of/IN
medication/NN
adherence/NN
in/IN
chronic/JJ
disease/NN
patients/NNS
./.
====================
A/DT
complete/JJ
identification/NN
of/IN
the/DT
genetic/JJ
influences/VBZ
for/IN
medication/NN
adherence/NN
appears/VBZ
feasible/JJ
,/,
because/IN
medication/NN
adherence/NN
is/VBZ
complexly/RB
influenced/VBN
by/IN
not/RB
only/RB
personality/NN
traits/VBZ
but/CC
also/RB
many/JJ
factors/NNS
,/,
including/VBG
socio-economic/JJ
factors/NNS
,/,
healthcare-related/JJ
factors/NNS
,/,
and/CC
demographic/JJ
factors/NNS
[/(
3/CD
]/)
./.
====================
Nevertheless/RB
,/,
identifying/VBG
genetic/JJ
associations/NNS
for/IN
poor/JJ
medication/NN
adherence/NN
in/IN
chronic/JJ
disease/NN
patients/NNS
requires/VBZ
further/RBR
research/NN
./.
====================
It/PRP
would/MD
be/VB
helpful/JJ
for/IN
physicians/NNS
to/TO
initiate/VB
personalized/VBN
medication/NN
therapy/NN
by/IN
modifying/VBG
treatment/NN
strategies/NNS
,/,
such/JJ
as/IN
changing/VBG
the/DT
route/JJ
of/IN
administration/NN
,/,
the/DT
complexity/NN
of/IN
treatment/NN
,/,
and/CC
the/DT
degree/NN
of/IN
behavioral/JJ
change/NN
required/VBN
,/,
for/IN
chronic/JJ
disease/NN
patients/NNS
with/IN
expected/VBN
poor/JJ
medication/NN
adherence/NN
from/IN
their/PRP$
genetic/JJ
background/NN
./.
====================
Summary/JJ
of/IN
the/DT
sampling/JJ
and/CC
quality/NN
control/NN
procedure/NN
./.
====================
KARE/NN
,/,
Korean/JJ
Association/NN
Resource/NN
project/VB
;/:
HTN/NN
,/,
hypertensive/JJ
patients/NNS
;/:
DM/NN
,/,
diabetes/VBZ
patients/NNS
;/:
SNP/NN
,/,
single/JJ
nucleotide/NN
polymorphism/NN
;/:
GWA/NNP
,/,
genome-wide/NN
association/NN
;/:
MAF/NN
,/,
minor/JJ
allelic/JJ
frequency/NN
;/:
HWE/NNP
,/,
Hardy-Weinberg/JJ
equilibrium/NN
./.
====================
Quantile-quantile/JJ
(/(
QQ/NN
)/)
plot/NN
and/CC
Manhattan/JJ
plot/NN
of/IN
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
for/IN
medication/NN
adherence/NN
./.
====================
(/(
A/NN
)/)
QQ/NN
plot/NN
shows/VBZ
the/DT
differences/NNS
between/IN
the/DT
observed/VBN
and/CC
expected/VBN
-log10/CD
(/(
p-value/NN
)/)
of/IN
the/DT
study/NN
results/VBZ
./.
====================
The/DT
red/JJ
line/NN
indicates/VBZ
the/DT
expected/VBN
distributions/NNS
under/IN
the/DT
null/JJ
hypothesis/NN
./.
====================
The/DT
gray/NN
shaded/VBD
region/NN
represents/VBZ
the/DT
95/CD
%/NN
confidence/NN
interval/JJ
./.
====================
(/(
B/NN
)/)
Manhattan/JJ
plot/NN
of/IN
single/JJ
nucleotide/NN
polymorphisms/NNS
for/IN
medication/NN
adherence/NN
./.
====================
X-axis/NN
represents/VBZ
chromosomes/NNS
./.
====================
Y-axis/NN
represents/VBZ
-log10/CD
(/(
p-values/NNS
)/)
obtained/VBN
by/IN
genome-wide/NN
association/NN
analysis/NN
./.
====================
The/DT
red/JJ
line/NN
indicates/VBZ
the/DT
suggestive/JJ
threshold/NN
for/IN
genome-wide/NN
significance/NN
(/(
p/NN
</JJR
1/CD
×/NN
10-5/CD
)/)
./.
====================
Regional/JJ
association/NN
plot/NN
of/IN
the/DT
most/JJS
significant/JJ
loci/NNS
associated/VBN
with/IN
medication/NN
adherence/NN
./.
====================
Purple/JJ
circle/NN
indicates/VBZ
the/DT
strongest/JJS
association/NN
(/(
rs6978712/NN
)/)
detected/VBN
in/IN
the/DT
genome-wide/NN
analysis/NN
./.
====================
Other/JJ
circles/NNS
indicate/VBP
SNPs/NNS
genotyped/VBD
in/IN
this/DT
study/NN
,/,
and/CC
their/PRP$
color/JJ
reflects/VBZ
the/DT
linkage/NN
disequilibrium/NN
(/(
r2/NN
)/)
with/IN
rs6978712/NN
./.
====================
The/DT
blue/JJ
line/NN
represents/VBZ
the/DT
recombination/NN
rates/NNS
in/IN
the/DT
1000/CD
Genome/NN
Mar/JJ
2012/CD
ASN/NN
population/NN
./.
====================
SNPs/NNS
,/,
single/JJ
nucleotide/NN
polymorphisms/NNS
;/:
ASN/NN
,/,
super/IN
population/NN
of/IN
the/DT
east/JJ
Asian/JJ
,/,
which/WDT
includes/VBZ
Han/JJ
Chinese/JJ
in/IN
Beijing/VBG
,/,
China/NN
;/:
Japanese/DT
in/IN
Tokyo/JJ
,/,
Japan/NNP
;/:
Southern/NN
Han/NN
Chinese/JJ
;/:
Chinese/JJ
Dai/NN
in/IN
Xishuangbanna/NN
,/,
China/NN
;/:
and/CC
Kinh/NN
in/IN
Ho/NN
Chi/NNP
Minh/NN
City/NN
,/,
Vietnam/NNP
./.
====================
Characteristics/NNS
of/IN
the/DT
study/NN
subjects/NNS
====================
SNPs/NNS
with/IN
p/NN
</JJR
1/CD
×/NN
10-5/CD
in/IN
the/DT
GWAS/NN
of/IN
235/CD
medication/NN
non-adherent/JJ
cases/NNS
and/CC
1,067/CD
medication/NN
adherent/JJ
controls/NNS
from/IN
the/DT
KARE/NN
cohort/NN
====================
